Celiac disease (gluten enteropathy) is a chronic immune-mediated disease that develops in genetically predisposed individuals in response to the ingestion of gluten, which is found predominantly in wheat, rye, and barley, with a global seroprevalence ranging from 0.5% to 2% of the general population. The disease can occur at any age and is characterized by inflammation of the small intestinal mucosa, villous atrophy, and impaired absorption of nutrients.
Tissue transglutaminase 2 plays a key role in the pathogenesis of celiac disease and is the major autoantigen associated with the production of characteristic celiac disease-related autoantibodies. Tissue transglutaminase is a calcium-dependent enzyme that modifies gluten peptides through deamidation, promoting activation of the gluten-specific T-cell immune response, followed by the development of conditions leading to inflammation and damage to the small intestinal mucosa.
Antibodies to tissue transglutaminase are one of the main serological markers of celiac disease and a recommended test for its laboratory screening and for monitoring the effectiveness of treatment in patients with a previously established diagnosis of celiac disease. To enable timely diagnosis of celiac disease, Vitrotest Bioreagent has developed and launched into production new high-quality test kits:
Vitrotest Transglutaminase-IgG, ELISA for the quantitative determination of IgG class antibodies to tissue transglutaminase (human tTG) in human serum or plasma:
- TK155 – 96 tests.
Vitrotest Transglutaminase-IgA, ELISA for the quantitative determination of IgA class antibodies to tissue transglutaminase (human tTG) in human serum or plasma:
- TK156 – 96 tests.
We invite you to review detailed information in the updated catalog on our website and place your order by contacting our sales department.